D. E. Shaw & Co., Inc. - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$455,717
-55.8%
13,152
-63.1%
0.00%
-100.0%
Q1 2024$1,031,065
-48.6%
35,640
-51.0%
0.00%
-50.0%
Q2 2023$2,007,587
-56.3%
72,686
-63.6%
0.00%
-60.0%
Q1 2023$4,588,868
+123.7%
199,516
+6.1%
0.01%
+150.0%
Q4 2022$2,051,473
+70.1%
188,036
+31.4%
0.00%
+100.0%
Q3 2022$1,206,000
-18.5%
143,075
+230.5%
0.00%0.0%
Q4 2021$1,480,000
-27.9%
43,286
-62.7%
0.00%
-50.0%
Q3 2021$2,054,000
-81.6%
115,913
-53.3%
0.00%
-80.0%
Q2 2021$11,141,000
+114.0%
248,235
+23.5%
0.01%
+100.0%
Q1 2021$5,205,000
-23.4%
200,980
-40.3%
0.01%
-16.7%
Q4 2020$6,791,000
-34.2%
336,856
-36.2%
0.01%
-45.5%
Q3 2020$10,320,000
-28.1%
527,833
-35.1%
0.01%
-35.3%
Q2 2020$14,356,000
+624.7%
812,946
+189.8%
0.02%
+466.7%
Q1 2020$1,981,000
-34.7%
280,534
-34.8%
0.00%0.0%
Q4 2019$3,035,000
-23.5%
430,517
+30.4%
0.00%
-40.0%
Q3 2019$3,966,000
-17.6%
330,169
-16.9%
0.01%
-16.7%
Q2 2019$4,811,000
+48.5%
397,278
+54.1%
0.01%
+50.0%
Q1 2019$3,239,000
+2353.8%
257,728
+1211.9%
0.00%
Q4 2018$132,000
+14.8%
19,645
+75.5%
0.00%
Q3 2018$115,000
-65.9%
11,195
-77.7%
0.00%
Q2 2018$337,000
-48.2%
50,261
+60.8%
0.00%
-100.0%
Q4 2017$650,00031,2510.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Johnson & Johnson Innovation - JJDC, Inc. 2,449,183$43,253,0008.50%
BVF INC/IL 2,367,288$41,806,0002.58%
RTW INVESTMENTS, LP 3,383,208$59,747,0001.68%
Novo Holdings A/S 824,169$14,555,0000.94%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,013,495$17,898,0000.52%
Sofinnova Investments, Inc. 326,064$5,758,0000.36%
FARALLON CAPITAL MANAGEMENT LLC 2,500,000$44,150,0000.35%
Virtus ETF Advisers LLC 21,639$382,0000.18%
Baker Brothers Advisors 1,911,446$33,756,0000.15%
King Wealth Management Group 22,000$389,0000.11%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders